I think there's still a cloud hanging over the reformulation story in investors' minds and until the results of ph 2 start rolling in, that scepticism will weigh down the sp. The other thing was that the last quarter was hardly stellar for Epichem, but then its quarterly revenues have bounced around a lot, so on its own it doesn't tell us much either way, but neither did it help the sp.
Ann: Monepantel reformulation successfully improves dose & taste, page-41
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
-0.005(2.86%) |
Mkt cap ! $82.69M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.0¢ | $55.34K | 315.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 537417 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 88847 | 4 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |